[ December 14, 2005 ]
University of Mississippi , MMV, and DNDi Agree to Collaborate on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis.
[ December 14, 2005 ]
[ Washington , DC – December 11, 2005 ]
First medicines developed by Drugs for Neglected Diseases initiative (DNDi) will be easier to use and less expensive than current ACTs, but action is needed to make sure the treatments reach patients.
[ Delhi, India – October 4, 2005 ]
The Drugs for Neglected Diseases initiative (DNDi), a not-for-profit drug development initiative, is collaborating with the Central Drug Research Institute (CDRI) Lucknow to test their library of compounds for possible activity against parasites that cause deadly neglected diseases such as kala azar and sleeping sickness.
[Marseille, France – September 13, 20051300 CET ]
DNDi presents results of Phase III clinical trials at Marseille conference
[ Tokyo , Japan – July 15, 2005 ]
Today, Drugs for Neglected Diseases initiative (DNDi) signed an agreement to conduct a joint research project with the Kitasato Institute in Japan to find a treatment for human African trypanosomiasis (sleeping sickness), a disease that kills tens of thousands in Africa each year.
[ June 8, 2005 ]
Call to governments to provide significant and sustained support to bring essential new drugs, vaccines, and diagnostics to people suffering and dying from neglected diseases.
[ Paris, April 8, 2005 ]
A collaborative agreement between the DNDi Foundation and Sanofi-Aventis to develop a new, easy-to-use malaria drug at target price below one dollar.
[ Geneva – April 5, 2006 ]
DNDi welcomes the final report of the WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). The report clearly states that it is imperative for governments to set global health priorities and promote innovation to develop and deliver much-needed medicines, vaccines, and diagnostics adapted to the needs of the sick and neglected in developing countries.
[ Geneva, Switzerland – March 2, 2005 ]
For Immediate Release : Africa’s first clinical research facility dedicated to visceral leishmaniasis (VL), was inaugurated by the Drugs for Neglected Diseases initiative (DNDi) on February 9 in the presence of the regional authorities of Ministry of Health, and members from Addis Ababa University (AAU).
[ Geneva , Switzerland – January 20, 2005 ]
The Drugs for Neglected Diseases initiative (DNDi) welcomes the warning issued by the World Health Organization (WHO) to stop selling artemisinin as a monotherapy for malaria, and thus, to prevent the development of resistance to the drug.